Analgesic Ketamine for Battlefield Use

The purpose of this RFI is to address the OPMED WPAC PMO’s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement.

All ketamine products for any route of administration will be considered, for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. Please see list of attachments for other instructions.